top of page
Share
  • LinkedIn
  • Youtube
  • X
  • Instagram
How we drive innovation
STORIES
MEETINGS
MEMBERS

Jens H. Vogel

President & COO of Mirai Bio - Former CEO of BI Fremont & Global Head of Biotech at Bayer Pharmaceuticals

Jens H. Vogel, SVP & Global Head of Biotech at Bayer is an advisor of GBX EVENTS

Ted Torphy

Dr. Ted Torphy brings to BioMotiv over 30 years of experience in the pharmaceutical industry with a successful record in both small-molecule and large-molecule drug discovery and preclinical development.

Jens H. Vogel, SVP & Global Head of Biotech at Bayer is an advisor of GBX EVENTS

Patrick Basanez

Director of GBX GROUP

Jens H. Vogel, SVP & Global Head of Biotech at Bayer is an advisor of GBX EVENTS

Thomas Herget

Head Silicon Valley & China Innovation Hub at Merck Group

Jens H. Vogel, SVP & Global Head of Biotech at Bayer is an advisor of GBX EVENTS

Behzad Mahdavi

CEO and Board Member of InnoGI Technologies

Jens H. Vogel, SVP & Global Head of Biotech at Bayer is an advisor of GBX EVENTS

Uwe Gottschalk

Operating Partner at Keensight Capital - Former CSO of Lonza

Jens H. Vogel, SVP & Global Head of Biotech at Bayer is an advisor of GBX EVENTS

Dave Malenfant

Dave Malenfant is Director, Outreach & Partnerships, Center for Supply Chain Innovation, at the Texas Christian University Neeley School of Business in Fort Worth, TX. He has more than 25 years of experience in driving change and performance

Jens H. Vogel, SVP & Global Head of Biotech at Bayer is an advisor of GBX EVENTS

Angela Vollstedt

Global Director, Cell & Gene Therapies Portfolio Management at Novartis

Jens H. Vogel, SVP & Global Head of Biotech at Bayer is an advisor of GBX EVENTS

Jesse McCool

CSO of Bionova Scientific - Former Co-Founder & CEO of Wheeler Bio

Dr. McCool has over 20 years of biotech experience with 15 years working for contract development and manufacturing organizations (CDMOs). Jesse is the CEO and Co-Founder of Wheeler Bio, a customer-first CDMO which integrates the discovery, optimization, and development stages of new biological entities enabling best-in-class delivery of preclinical and clinical materials to IND sponsors. Jesse previously held technical and executive leadership positions at Lonza, Mascoma (Lallemond) and Cytovance Biologics where he helped to position the company for growth and M&A. Following the 2015 acquisition by Hepalink, Jesse served as Cytovance board director, CTO and CEO while supporting global integration and corporate strategy. He left Cytovance following the successful 2020 Hong Kong listing (SZSE:002399, HKEx:9989). Jesse earned a Ph.D. in Microbiology from the University of Massachusetts at Amherst in 2003. He completed his postdoctoral work at Dartmouth College Thayer School of Engineering (Hanover, NH) and additional technical training at the Delft University of Technology (The Netherlands). In addition to his industry experience, Jesse is an established public speaker, researcher and peer-reviewed journal author and contributor.

Speakers
bottom of page